Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its self-developed first-in-class bispecific antibody–drug conjugate (ADC), Izalontamab Bretecan (BL-B01D1, “iza-bren”), in combination with a PD-1 monoclonal antibody (mAb), has been granted Breakthrough Therapy Designation (BTD) for the first-line treatment of patients with PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | China’s Center for Drug Evaluation (CDE), NMPA |
| Designation Type | Breakthrough Therapy Designation |
| Product | Izalontamab Bretecan (BL-B01D1 / iza-bren) + PD-1 mAb combination |
| Indication | First-line treatment of PD-L1-positive locally recurrent unresectable or metastatic TNBC |
| Announcement Date | 22 Sep 2026 |
| Cumulative BTD Count | 8 indications on China’s Breakthrough Therapy list; 1 indication granted BTD by the U.S. FDA |
| Regulatory Effect | Qualifies the regimen for expedited development and review engagement with the CDE |
Drug Profile & Mechanism of Action
- Molecule: Izalontamab Bretecan (BL-B01D1 / iza-bren), a first-in-class bispecific ADC self-developed by Biokin through its U.S.-based R&D arm SystImmune.
- Modality: A dual-targeting bispecific antibody conjugated to a cytotoxic topoisomerase I inhibitor payload, designed to broaden tumor antigen coverage and enhance payload delivery versus single-target ADCs.
- Combination Rationale: Pairing the ADC with a PD-1 mAb aims to convert ADC-mediated tumor cell killing into a durable anti-tumor immune response in the first-line metastatic TNBC setting, where PD-L1 positivity identifies patients most likely to benefit from checkpoint blockade.
- Designation Breadth: With eight China BTDs and one FDA BTD, iza-bren ranks among the most broadly recognized investigational ADCs originating from China, spanning multiple solid tumor types.
BMS Collaboration & Milestone Economics
| Item | Detail |
|---|---|
| Agreement | Exclusive license and collaboration for iza-bren, signed December 2023 |
| Parties | SystImmune (Biokin subsidiary) and Bristol-Myers Squibb (NYSE: BMY) |
| Upfront Payment | USD 800 million, non-refundable and non-creditable – received |
| First Near-Term Milestone | USD 250 million – received |
| Second Near-Term Milestone | USD 250 million contingent payment – conditions officially triggered |
| Trigger Event | Milestone achieved by IZABRIGHT-Lung02, the global pivotal Phase III trial for iza-bren |
| Expected Receipt | Near future, per company announcement |
Market Impact & Outlook
- Unmet Need in TNBC: PD-L1-positive locally recurrent unresectable or metastatic TNBC remains an aggressive subtype with high relapse risk; a first-line ADC–immunotherapy combination with BTD status signals potential for a substantial improvement over current standards of care.
- Cash Milestone Validation: Upon receipt of the second USD 250 million payment, cumulative near-term cash under the BMS agreement will total USD 1.3 billion (USD 800 million upfront + USD 500 million in near-term milestones), underscoring BMS’s commitment to the asset.
- Global Clinical Momentum: The IZABRIGHT-Lung02 milestone confirms progression of iza-bren’s global pivotal program alongside BMS, extending the asset’s value story beyond China into worldwide registrational development.
- Pipeline Optionality: Eight domestic BTD indications provide multiple potential registrational paths, allowing Biokin/SystImmune to sequence filings by data maturity and competitive landscape.
- Sector Signal: Continued FDA and CDE recognition of China-originated ADCs reinforces the licensing-out model as a durable monetization route for Chinese biopharma innovators.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory review timelines, clinical trial outcomes, milestone payment receipt, and commercial expectations for Izalontamab Bretecan. Actual results may differ materially due to risks including final regulatory determinations, trial readouts, collaboration dynamics, and competitive developments.-Fineline Info & Tech
